` ACE (Ascelia Pharma AB) vs OMX Stockholm 30 Comparison - Alpha Spread

ACE
vs
O
OMX Stockholm 30

Over the past 12 months, ACE has significantly outperformed OMX Stockholm 30, delivering a return of +88% compared to the OMX Stockholm 30's +4% growth.

Stocks Performance
ACE vs OMX Stockholm 30

Loading
ACE
OMX Stockholm 30
Add Stock
www.alphaspread.com

Performance Gap
ACE vs OMX Stockholm 30

Loading
ACE
OMX Stockholm 30
Difference
www.alphaspread.com

Performance By Year
ACE vs OMX Stockholm 30

Loading
ACE
OMX Stockholm 30
Add Stock

Competitors Performance
Ascelia Pharma AB vs Peers

OMX Stockholm 30
ACE
ABBV
AMGN
GILD
VRTX
Add Stock

Ascelia Pharma AB
Glance View

Market Cap
556.9m SEK
Industry
Biotechnology

Ascelia Pharma AB engages in the research and development of pharmaceutical products for the treatment of cancer and cancer-related diseases. The company is headquartered in Malmo, Skane. The company went IPO on 2019-03-13. The firm identifies, acquires and develops differentiated, underappreciated and derisked investigational medicinal drug candidates to make them available to cancer patients. The firm's pipeline includes Mangoral and Oncoral. Mangoral is a medical imaging drug candidate for use in liver Magnetic Resonance Imaging (MRI) for detection and localization of liver metastases in patients with impaired kidneys, which has completed phase II of clinical studies. Oncoral is a tablet formulation of chemotherapeutic agent irinotecan under clinical development for the treatment of gastric cancer. The company has completed phase I of clinical studies.

ACE Intrinsic Value
33.4 SEK
Undervaluation 86%
Intrinsic Value
Price
Back to Top